Screening for advanced liver fibrosis in overweight and obese patients with NAFLD

References

[1] 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017.Lancet2018;392:1736-88 PMCID:PMC6227606

[2] 2017 Cirrhosis Collaborators. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.Lancet Gastroenterol Hepatol2020;5:245-66 PMCID:PMC7026710

[3] Powell EE,Rinella M.Non-alcoholic fatty liver disease.Lancet2021;397:2212-24

[4] Cusi K.Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications.Gastroenterology2012;142:711-725.e6

[5] Friedman SL,Rinella M.Mechanisms of NAFLD development and therapeutic strategies.Nat Med2018;24:908-22 PMCID:PMC6553468

[6] Romeo S,Valenti L.Leveraging human genetics to identify potential new treatments for fatty liver disease.Cell Metab2020;31:35-45

[7] Stefan N.Causes, consequences, and treatment of metabolically unhealthy fat distribution.Lancet Diabetes Endocrinol2020;8:616-27

[8] Targher G,Byrne CD.Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach.Lancet Gastroenterol Hepatol2021;6:578-88

[9] Stefan N.A global view of the interplay between non-alcoholic fatty liver disease and diabetes.Lancet Diabetes Endocrinol2022;10:284-96

[10] Lonardo A,Osna N.Effect of cofactors on NAFLD/NASH and MAFLD. A paradigm illustrating the pathomechanics of organ dysfunction.Metab Target Organ Damage2022;2:12. PMCID:PMC9453927

[11] Huang DQ,Kono Y,El-Serag HB.Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer.Cell Metab2022;34:969-977.e2 PMCID:PMC9762323

[12] Mantovani A,Beatrice G,Byrne CD.Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals.Gut2021;70:962-9

[13] Mantovani A,Petracca G.Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis.Lancet Gastroenterol Hepatol2021;6:903-13

[14] Lonardo A,Petta S,Byrne CD.Metabolic mechanisms for and treatment of NAFLD or NASH occurring after liver transplantation.Nat Rev Endocrinol2022;18:638-50

[15] Ekstedt M,Nasr P.Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.Hepatology2015;61:1547-54

[16] Angulo P,Dam-Larsen S.Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease.Gastroenterology2015;149:389-97.e10 PMCID:PMC4516664

[17] Dulai PS,Patel J.Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis.Hepatology2017;65:1557-65 PMCID:PMC5397356

[18] Sanyal AJ,Clark J.NASH Clinical Research Network (CRN)Prospective study of outcomes in adults with nonalcoholic fatty liver disease.N Engl J Med2021;385:1559-69 PMCID:PMC8881985

[19] Bravo AA,Chopra S.Liver biopsy.N Engl J Med2001;344:495-500

[20] Davison BA,Cotter G et al., Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials.J Hepatol2020;73:1322-32

[21] Tamaki N,Huang DQ.Noninvasive assessment of liver fibrosis and its clinical significance in nonalcoholic fatty liver disease.Hepatol Res2022;52:497-507 PMCID:PMC9718363

[22] Kim BK,Imajo K.Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD.J Hepatol2022;77:1482-90

[23] Kanwal F,Younossi Z.Preparing for the NASH epidemic: a call to action.Metabolism2021;122:154822

[24] Kanwal F,Adams LA.Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease.Gastroenterology2021;161:1657-69 PMCID:PMC8819923

[25] Bril F,Lomonaco R.Assessing strategies to target screening for advanced liver fibrosis among overweight and obese patients.Metab Target Organ Damage2022;2:11 PMCID:PMC9400455

[26] Lomonaco R,Bril F.Advanced liver fibrosis is common in patients with type 2 diabetes followed in the outpatient setting: the need for systematic screening.Diabetes Care2021;44:399-406 PMCID:PMC7818321

[27] Barb D,Stokes ME,Cusi K.Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease.Obesity2021;29:1950-60 PMCID:PMC9290591

[28] Bril F,Caulfield MP.Performance of plasma biomarkers and diagnostic panels for nonalcoholic steatohepatitis and advanced fibrosis in patients with type 2 diabetes.Diabetes Care2020;43:290-7

[29] Cusi K,Barb D.American association of clinical endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: co-sponsored by the American association for the study of liver diseases (AASLD).Endocr Pract2022;28:528-62

[30] Younes R,Govaere O.Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease.J Hepatol2021;75:786-94

[31] Qadri S,Lønsmann I.Obesity modifies the performance of fibrosis biomarkers in nonalcoholic fatty liver disease.J Clin Endocrinol Metab2022;107:e2008-20 PMCID:PMC9016464